275 related articles for article (PubMed ID: 29151523)
21. Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer.
Kimura M; Usami E; Teramachi H; Yoshimura T
J Oncol Pharm Pract; 2018 Sep; 24(6):403-411. PubMed ID: 28436252
[TBL] [Abstract][Full Text] [Related]
22. [Case Report of Four Patients Received Ramucirumab Monotherapy as Second-Line Chemotherapy for Advanced Gastric Cancer].
Onodera K; Ichiyanagi A; Ueno A; Tani M; Sato S; Shimizu H; Kaneto H
Gan To Kagaku Ryoho; 2021 Sep; 48(9):1169-1171. PubMed ID: 34521798
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
24. [A Case of Lymph Nodes Metastases of Gastric Neuroendocrine Carcinoma Treated with Nivolumab and Showing Complete Response].
Wada N; Takachi K; Shirosaki Y; Fujiwara M; Fukuda N; Matsuura Y; Munakata K; Takiuchi D; Hama N; Ota H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1546-1547. PubMed ID: 38303336
[TBL] [Abstract][Full Text] [Related]
25. [A case of recurrent gastric cancer during adjuvant chemotherapy with S-1, treated by S-1 combination chemotherapy].
Shibata N; Eto TA; Asada T; Takaya T; Tanaka S; Shimayama T; Imada S; Futami S; Hidaka H; Chijiiwa K
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1745-8. PubMed ID: 19838040
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas.
Liu DJ; Fu XL; Liu W; Zheng LY; Zhang JF; Huo YM; Li J; Hua R; Liu Q; Sun YW
World J Gastroenterol; 2017 Jan; 23(3):516-524. PubMed ID: 28210088
[TBL] [Abstract][Full Text] [Related]
27. A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas.
Ueda S; Satoh T; Gotoh M; Gao L; Doi T
Oncologist; 2015 May; 20(5):493-4. PubMed ID: 25888272
[TBL] [Abstract][Full Text] [Related]
28. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
[TBL] [Abstract][Full Text] [Related]
29. A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites.
Matsumoto H; Kawazoe A; Shimada K; Fukuoka S; Kuboki Y; Bando H; Kojima T; Ohtsu A; Yoshino T; Doi T; Shitara K
BMC Cancer; 2018 Jan; 18(1):120. PubMed ID: 29385993
[TBL] [Abstract][Full Text] [Related]
30. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma.
Okita NT; Kato K; Takahari D; Hirashima Y; Nakajima TE; Matsubara J; Hamaguchi T; Yamada Y; Shimada Y; Taniguchi H; Shirao K
Gastric Cancer; 2011 Jun; 14(2):161-5. PubMed ID: 21327441
[TBL] [Abstract][Full Text] [Related]
31. Perforation of gastric metastasis during chemotherapy with ramucirumab.
Kobashi M; Kanzaki H; Okada H
Curr Probl Cancer; 2021 Apr; 45(2):100666. PubMed ID: 33129565
[TBL] [Abstract][Full Text] [Related]
32. Ramucirumab Plus Paclitaxel: A Possible New Chemotherapy Regimen for Neuroendocrine Carcinoma of the Stomach.
Motoo Y
Intern Med; 2018 Mar; 57(5):631-632. PubMed ID: 29151542
[No Abstract] [Full Text] [Related]
33. A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan.
Chen Y; Katayose T; Nagaoka S; Piao Y; Yamaguchi K; Asou H
Gastric Cancer; 2021 Nov; 24(6):1320-1329. PubMed ID: 34050432
[TBL] [Abstract][Full Text] [Related]
34. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Rinke A; Gress TM
Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-line Chemotherapy in Japan.
Saito S; Muneoka Y; Ishikawa T; Akazawa K
Clin Ther; 2017 Dec; 39(12):2380-2388. PubMed ID: 29175097
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
[TBL] [Abstract][Full Text] [Related]
37. Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Hanada M; Noguchi T; Yamaoka T
Cancer Sci; 2007 Mar; 98(3):447-54. PubMed ID: 17214744
[TBL] [Abstract][Full Text] [Related]
38. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
Shitara K; Muro K; Shimada Y; Hironaka S; Sugimoto N; Komatsu Y; Nishina T; Yamaguchi K; Segawa Y; Omuro Y; Tamura T; Doi T; Yukisawa S; Yasui H; Nagashima F; Gotoh M; Esaki T; Emig M; Chandrawansa K; Liepa AM; Wilke H; Ichimiya Y; Ohtsu A
Gastric Cancer; 2016 Jul; 19(3):927-38. PubMed ID: 26510663
[TBL] [Abstract][Full Text] [Related]
39. Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.
Satake H; Sagawa T; Fujikawa K; Hatachi Y; Yasui H; Kotaka M; Kato T; Tsuji A
Cancer Chemother Pharmacol; 2018 Nov; 82(5):839-845. PubMed ID: 30167847
[TBL] [Abstract][Full Text] [Related]
40. Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.
Takahari D; Shimada Y; Takeshita S; Nishitani H; Takashima A; Okita N; Hirashima Y; Kato K; Hamaguchi T; Yamada Y; Shirao K
Gastric Cancer; 2010 Aug; 13(3):186-90. PubMed ID: 20820988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
